^
Association details:
| Biomarker: | TMB-L |
|---|---|
| Cancer: | Mast Cell Leukemia |
| Drug Class: | T-lymphocyte cell therapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BASELINE TUMOR BURDEN CORRELATES WITH RESPONSE BUT NOT TOXICITIES IN PATIENTS TREATED WITH BISPECIFIC ANTI-CD20, ANTI-CD19 CAR-T CELLS
Published date:
05/12/2021
Excerpt:
...we included patients from the previously mentioned Phase 1 clinical trial treated with LV20.19 CAR T-cells (NCT03019055)...Mean baseline LDH was significantly lower in patients who had a response (CR or PR) (243 vs 600, p=0.03) and in those with CR (196 vs 504.2, p=0.046). Low tumor burden on PET/CT was associated with overall response (CR or PR) vs PD (p=0.026) but not with a CR (p=0.13).
